GlassScriptPhysician profile
Rita Komboz
NPI 1275508541
$1,501.77
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $218 · 2021: $269 · 2022: $275.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.54 | 2019-2022 | |
| Amgen INC. | $225.33 | 2019-2022 | |
| Pfizer INC. | $212.51 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $196.59 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $108.78 | 2019-2022 | |
| Janssen Biotech, INC. | $88.15 | 2019-2022 | |
| Glaxosmithkline, LLC. | $53.96 | 2019-2022 | |
| Ucb, INC. | $28.76 | 2019-2020 | |
| Depuy Synthes Sales INC. | $28.31 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $27.30 | 2021 | |
| Horizon Therapeutics Plc | $26.72 | 2020 | |
| Genzyme Corporation | $26.40 | 2019 | |
| Radius Health, INC. | $15.90 | 2020 | |
| Hikma Pharmaceuticals USA | $12.99 | 2020 | |
| Fidia Pharma USA INC. | $10.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Komboz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.